Coverage news
Every coverage development we have covered, newest first.
3 dated coverage items. Most recent: Medicare GLP-1 Bridge reported as an inflection point in month one (2026-08-05).
All-in monthly cost at 10 mg
What this beat covers
Insurance and employer coverage for the approved products, which beats every cash route on this site when it applies. Coverage follows indications rather than molecules, so the practical question is never whether a plan covers tirzepatide but whether it covers your indication.
We track this beat because the most valuable thing this site can tell a cash-paying reader is sometimes that they should not be a cash-paying reader.
Stories in this category
Medicare GLP-1 Bridge reported as an inflection point in month one
Access expanded to roughly 20 million eligible beneficiaries, with prior authorisation reportedl…
More employers drop weight-management GLP-1 coverage at renewal
Withdrawals land mid-treatment, and interruption is the mechanism that undoes results.…
States gain the option to expand GLP-1 access through Medicaid
A route that did not exist for the lowest-income patients — but optional, so it will be a patchw…
How to read a dated item
Every story carries the date we recorded it and links to what we read. Nothing here is undated, because an undated claim about a market that reprices this often is not usable. Where an item concerns a price, the figure is repeated with its dose and its fee basis attached rather than left to be inferred from the headline.
If an item is wrong, it gets a correction with a date rather than a silent edit. The full log is at corrections, and it includes errors we found in our own work.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.